Cancer-Killing virus joins forces with immunotherapy in new trial

NCT ID NCT06889493

Recruiting now Disease control Sponsor: Peter Hosein, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a cancer-killing virus (SVV-001) injected directly into tumors, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 36 adults with advanced neuroendocrine tumors that have worsened after standard treatment. The main goals are to find the safest dose and dosing schedule, and to see if the combination can control the disease. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Seneca Valley Virus (SVV-001) plus nivolumab and ipilimumab
What this could lead to: If successful, this could point toward a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 36 participants, so safety and dosing are still being figured out. The combination may cause significant side effects or may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS NEUROENDOCRINE; CARCINOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.